Why Outcome Measures in Dermatology Are Becoming Patient Centric

Jennifer Nergard-Martin, Fariha Siddiqui, Ajay Kailas, Monet Winslow, James A. Solomon

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Many “validated” treatment outcome assessments in clinical trials fail to include outcomes important to patients. This review will focus on recent efforts to revise and make patient-centric clinical trial outcomes used in psoriasis, acne vulgaris, atopic dermatitis, and hidradenitis suppurativa. Recent Findings: Over recent years, international coalitions have been formed to revise the investigator-oriented “validated” measures (e.g., PASI, IGA) in order to incorporate outcomes important to patients These not only include quality of life (QoL) assessments but also the anatomic location, physical discomfort, and appearance. This review discusses work underway to include patients in formatting revised outcome assessments. Summary: Historically, outcome measures have been developed by clinicians and pharmaceutical companies for use in clinical trials. Nonetheless, a movement is underway supported by regulatory agencies, government officials, and patient advocacy groups to include patients in the process of redesigning clinical trial outcome measures.

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalCurrent Dermatology Reports
Issue number3
StatePublished - Sep 1 2017
Externally publishedYes


  • HOME
  • Patient reported outcomes (PRO)
  • Patient-centric outcome assessment
  • Patient-centric treatment outcome

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Why Outcome Measures in Dermatology Are Becoming Patient Centric'. Together they form a unique fingerprint.

Cite this